NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.enterabio.comEntera Bio will participate in the 2025 BIO International Convention from June 16-19, 2025, in Boston, MA.
conference talkEntera Bio is expected to complete a Phase 1/2 clinical trial on 1 May 2026, evaluating new oral formulations of hPTH(1-34) tablets (EBP11 and EBP22) against its existing EBP05 tablets and the injectable osteoporosis drug Forteo. The study aims to compare pharmacokinetics and safety profiles, potentially supporting further development of oral parathyroid hormone therapies for osteoporosis and related conditions.
trial completion